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Introduction
Accumulating epidemiological and clinical results [1–3]
show strong associations of high plasma fibrinogen levels
with both the onset and progression of arterial disease at
all three main sites (ie heart, brain and lower extremities).
High levels are also associated with venous thrombosis
Abstract
Background  Raised levels of both triglycerides and fibrinogen, each of which are reduced by
bezafibrate, may contribute to lower extremity arterial disease (LEAD). This condition is characterized
by a particularly high incidence of coronary heart disease (CHD) and stroke, but is little studied thus far
in randomised controlled trials.
Method Patients were recruited through 85 practices in the British Medical Research Council General
Practice Research Framework and through nine hospital vascular clinics. The treatment regimen, which
is double-blind and placebo-controlled, is bezafibrate 400 mg/day. The 1568 patients recruited
represent 86% of those eligible at screening.
Results None of the anticipated side effects (mainly gastrointestinal) differed between the two groups.
Nearly 80% of the total person-years accrued at 3 years were spent on trial treatment. Bezafibrate
significantly reduced total cholesterol by approximately 8.0% and low-density lipoprotein (LDL)-
cholesterol by approximately 9.0%, and increased high-density lipoprotein (HDL)-cholesterol by
approximately 11.0% initially, falling to about 6.0% at 3 years. Triglycerides were significantly reduced
by about 23.0% and fibrinogen by about 14.0%. Plasma creatinine rose by approximately 11% in
those on active treatment. All of these effects were highly significant (P < 0.0001). Bezafibrate had no
effect on the level of C-reactive protein (CRP).
Conclusion The trial recruited an unusually high proportion of eligible patients, ensuring the general
applicability of its results. The fibrinogen-lowering and lipid-modifying effects of bezafibrate were
confirmed. Although bezafibrate lowers fibrinogen, it has no effect on CRP; this suggests that the
reduction in fibrinogen is due to an effect on its metabolism rather than suppression of an
inflammatory response.
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[4], and there is some evidence [5] that they impair the
outcome of interventions such as percutaneous coronary
angioplasty. Laboratory studies have indicated how fib-
rinogen affects several pathways that are known or sus-
pected to be involved in thrombogenesis, principally the
degree of blood viscosity, the amount of fibrin produced
when the coagulation process is initiated, clot deformabil-
ity, platelet aggregability and atherogenesis [6]. This evi-
dence suggests that high fibrinogen levels are of causal
significance. On the other hand, studies of polymorphisms
associated with fibrinogen levels [7,8] have been equivo-
cal regarding the relationship of the former with clinical
events of CHD.
Thus, the effects of lowering levels of fibrinogen need to
be established through randomised trials so that the role
of fibrinogen can be clarified, as well as identifying the
clinical implications. This additional evidence would be
necessary anyway, as it was for cholesterol, but particu-
larly because of the view that raised fibrinogen levels are
an acute-phase or chronic-phase response to the inflam-
matory nature of atheroma, and are therefore merely
markers of underlying vessel wall disease and have no
pathogenetic significance.
Apart from ancrod, which is used only in emergency situa-
tions and has to be given by infusion, there are at present
no selective fibrinogen-lowering agents. However, most
fibrates, including bezafibrate, lower fibrinogen levels as
well as having the lipid-modifying properties for which they
were originally introduced. Depending crucially on the
extent to which it may or may not eventually be possible to
apportion any clinical benefits between its fibrinogen-low-
ering and lipid-modifying effects, trials of bezafibrate may
therefore offer opportunities for assessing the effects of
lowering fibrinogen levels
The Lower Extremity Arterial Disease Event Reduction
(LEADER) trial of bezafibrate is being carried out in men
with LEAD. This condition was selected partly because
raised levels of triglycerides may be contributory [9] and
the greatest effect of bezafibrate is in lowering triglyc-
erides, but also because of the high incidence of CHD
events and strokes in patients with LEAD.
Recruitment to the trial started in 1992 and was almost
completed in 1997, with a few further entrants in 1998. The
present report describes the procedures and early stages of
the trial, and the treatment effects of bezafibrate on fibrino-
gen, lipids and other variables during the first 3 years.
Method
Recruitment
LEADER is being carried out in men on the lists of 85
practices throughout the UK in the British Medical
Research Council General Practice Research Frame-
work and through nine hospital vascular clinics. In the
Framework practices, patients with suspected or definite
LEAD were identified either through diagnostic indices
or through a listing of those taking any medications that
may be used in treating LEAD and its complications. The
research nurses then reviewed the notes of all of these
men in order to exclude those who did not in fact have
LEAD. Men with LEAD were ineligible for the following
reasons: unstable angina, unless or until it was con-
trolled; serum total cholesterol less than 3.5 mmol/l or
more than 8.0 mmol/l (discussed in further detail below);
significant renal or hepatic disease; a known hepatitis B
or C or HIV positive status; malignant disease (other
than non-melanoma skin cancer) within the past 5 years;
they were taking or likely to need lipid-lowering agents or
monamine oxidase inhibitors; they were unlikely to
comply with trial treatment or procedures; they were in
another trial; or at the discretion of the general practi-
tioner for other reasons. There were no upper or lower
age limits. Those who had had a myocardial infarct or
stroke were eligible for the trial provided that their
general management was stable, again at the discretion
of the general practitioner.
Men were then sent an invitation to attend a screening
visit for an explanation of the trial. At the following base-
line medical examination at least 1 week later for those
willing to proceed, eligibility for the trial was confirmed by
a positive response to the Edinburgh Claudication Ques-
tionnaire administered by the research nurse. Occasional
atypical responses, such as pain on walking in the thigh
or buttock, but not in the calf, were assessed by the
doctor, although LEAD was confirmed at a second visit
for a medical examination by the doctor in all cases,
typical or not. Blood was drawn to identify those with lipid
levels that the general practitioner might wish to treat with
non-fibrate agents, or those with evidence of renal impair-
ment defined in these men (on expert advice) as serum
creatinine of 150 µmol/l or more, because both of these
situations increase the risk of muscle necrosis in those
taking bezafibrate. All blood tests were performed twice
before starting treatment: once at the baseline medical
examination and again a day or so before the men started
taking tablets.
Apart from fibrinogen (Clauss method), total cholesterol,
LDL-cholesterol (calculated) and HDL-cholesterol (precip-
itation method) levels, triglycerides (non-fasting), creati-
nine and alkaline phosphate were also measured, alkaline
phosphatase providing a measure of compliance with
treatment. LDL-cholesterol could not be measured
directly, so there may be some imprecision in the results
from men with high triglyceride levels (which were from
non-fasting samples in order to ensure that as high a pro-
portion as possible of those eligible would enter and
remain in the trial).c
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Men completed questionnaires on symptoms, mostly the
known possible side effects of bezafibrate, but also other
symptoms such as impotence that are often attributed to
treatment by older men, and on quality of life and use of
health and related services. In some practices tests of
cognitive function and of visual acuity were carried out
because high fibrinogen levels may impair cerebral blood
flow through its influence on viscosity [10] and contribute
to age-related macular degeneration [11], either or both of
which might therefore benefit from fibrinogen lowering.
Procedures in the hospital clinics were similar, apart from
the initial identification of patients, which was through
clinic attendance or diagnostic indices.
Trial treatment
Approximately 1 month after the medical examination, and
provided that the creatinine result was within the specified
limit, random assignment of trial treatment was initiated, bal-
anced between active and placebo treatment within each
practice or hospital clinic. Labels identifying containers with
either active or placebo tablets were removed at the trial co-
ordinating centre, labelled with the man’s name and trial
number, and sent to the practices and hospital clinics.
Active treatment was bezafibrate 400 mg/day (Bezalip-
Mono; Boehringer Mannheim UK/Roche Products Ltd,
Welwyn Garden City, UK) for men with creatinine levels
below 135 µmol/l and was placebo controlled, with all
tablets identical in appearance. Men with entry creatinine
levels between 135 and 149 µmol/l took 400 mg on alter-
nate days. In men taking daily treatment (i.e. those with cre-
atinine less than 135 µmol/l at entry), this was changed to
alternate day treatment if levels rose to 155 µmol/l unless
or until levels rose to 170 µmol/l or more, in which case
men were withdrawn from trial treatment. These changes
were made for all men, whether they were on active or
placebo treatment. (Raised creatinine levels generally fell to
previous levels after withdrawal from trial treatment.)
The trial was approved by the 69 Local Research Ethics
Committees that were responsible for the participating
practices and hospitals. The question most frequently
raised before final approval was given was whether men
should routinely be taking statins, largely regardless of
cholesterol levels, but particularly in those with high levels
and those who had previously had myocardial infarcts.
When the trial began, it was clear that expense would
often preclude this, although participation in the trial would
at least provide a 50% chance of receiving lipid-modifying
treatment. Thus, after verbal and/or written exchanges
with several committees, the entry criteria were accepted.
As a matter of principle, no advice was given to the
doctors responsible for the day-to-day management of
recruited patients regarding treatments outside the
requirements of the trial. However, the attention of general
practitioners, whether in Framework practices or those
responsible for patients recruited through the hospitals,
was drawn to the results of the Scandinavian Simvastatin
Survival Study [12], and decisions regarding treatment
with a statin were left to their discretion. General practi-
tioners and hospital doctors were also given pre-treatment
cholesterol levels so that they could initiate statin treat-
ment before trial treatment started if they wished to do so,
and they were also notified regarding raised levels at
follow-up visits. In 1999, the data monitoring and ethics
committee of the trial recommended that reminder letters
should be sent to doctors caring for all trial patients with
total cholesterol levels above 7.0 mmol/l, which resulted in
several men being started on statin treatment and their
withdrawal from trial treatment.
Follow up and ascertainment of endpoints
Men were seen 1 month after treatment started and then
at 3-month intervals to receive new supplies of tablets.
Blood for repeat tests was taken at 1 and 3 months, and
then at 6-month intervals. At the 1-month and 3-month
visits men completed further questionnaires regarding
symptoms and health service usage. At the annual visits,
nurses asked about possible endpoint events (ie myocar-
dial infarction and stroke). Details regarding such events
were mostly provided by the Framework practices as they
occurred, but were also sought at an annual check
through the practice notes for each patient. Such details
included events in those who had withdrawn from trial
treatment, because these patients were nearly all known
to the practices throughout the course of their routine clin-
ical care. Few men moved from their addresses at the time
of recruitment, and they will be followed up as described
elsewhere [13]. In the hospitals, checks for endpoints
were also made annually (as for men in the general prac-
tices). Hospital patients who withdrew from trial treatment
were given change of address cards to be returned if they
moved and were sent annual questionnaires about their
progress. All deaths, whether in general practice or in hos-
pital participants, were automatically notified by the
National Health Service Central Registry.
All possible endpoint episodes notified were documented
and assessed independently and without knowledge of trial
treatment allocation [13]. Follow up for recording of events
was continued in those who had withdrawn or been with-
drawn from trial treatment. Initially, the occurrence of proba-
ble endpoints led to discontinuation of trial treatment.
However, because patients who had had previous heart
attacks or strokes were eligible for the trial and because of
requests to continue treatment from some patients in whom
treatment had been discontinued following an event, treat-
ment was restarted after the acute episode was resolved
and recurrent episodes were recorded. Thus, it will be pos-
sible to give results according to the numbers of men who
experienced events and according to the number of events.
Available online http://cvm.controlled-trials.com/content/2/4/195Participation in the trial was for a minimum of 3 years and
sample size (indicated below) was based on participation
for 4 years. Earlier trials in the Framework showed consid-
erable advantages in a common finishing date, so those
who entered the trial early on were asked to consider con-
tinuing until this date, and will therefore have been in the
trial for up to 8 years. At 3 years, only 11 out of 340
(3.2%) men asked to continue declined to do so.
Cognitive function was re-assessed once, after 15 months,
and visual acuity was assessed annually.
In just under 200 men, CRP was measured [14] at
screening and trial entry (i.e. twice before treatment start),
and then at 1, 3 and 6 months. Values are log-transformed
and geometric means given.
Statistical analysis
Cardiovascular mortality and incidence in LEAD have
been reported in several studies and estimates vary. It
appears probable that approximately 13% of patients with
LEAD die of major coronary events or strokes over a 4-
year period [15]. It has been assumed that there are 1.5
nonfatal events for each fatal event, and therefore some
33% of trial patients were likely to experience an event.
Increasing the duration of participation beyond 4 years for
some men and including recurrences (see above) will
increase the numbers of events. About two-thirds of the
men were taking platelet-active agents (mostly aspirin),
and this was expected to reduce the proportion of men
having an event from 33% to approximately 28% in the
placebo group. Allowing for a further attenuation of any
treatment effect due to 15% of men withdrawing from
treatment, a 30% reduction in endpoints suggests an
event-rate of approximately 20% in those on active treat-
ment compared with 28% in those in the placebo group.
This effect could be detected in 1500 men at the 5% level
of significance with 80% power. CHD events, fatal and
nonfatal events separately, and stroke separately are sec-
ondary endpoints.
In assessing the effect of active treatment on biochemical
variables, the change from baseline within each individual
was calculated and differences in these changes between
groups were tested by unpaired t tests.
Results
Recruitment
Recruitment is illustrated in Fig. 1. Of approximately 3200
men invited to attend the first or screening visit (precise
numbers not recorded), either in the Framework or in the
hospitals, 2505 (78%) did so. Of the 2505 men who
attended 937 (37%) were excluded at screening, at the
baseline medical examination or at trial entry for the
reasons shown in Table 1. Most of the 277 men who were
considered not to have LEAD came from general practice,
where identification of patients was largely through pre-
scribing information that was often not specific for LEAD
(see above). The 1568 patients entered represent 86% of
the 1816 who were eligible. Inadvertently, 10 men with
entry cholesterol levels of more than 8.0 mmol/l were
entered.
Characteristics of participants
Table 2 summarizes the characteristics of the men
recruited. Their mean age was 69 years, ranging from 35 to
92 years. Just over 4% claimed never to have smoked. The
current smokers had smoked for 49 years on average and
the ex-smokers for 39 years. Approximately two-thirds were
taking platelet-active agents, nearly all of which were in the
form of aspirin. Over 30% had previously had myocardial
infarcts or strokes or had stable angina, this figure being
more than those for individual conditions because some
men had a history of more than one of them. Table 2 also
shows entry values of fibrinogen and lipids. 
Symptomatic and biochemical effects of treatment
Table 3 gives the responses from all the 15,279 on-treat-
ment symptom questionnaires that were completed at
follow-up visits up to March 2001 by men in the trial for at
least 3 years. No symptoms were reported more frequently
by those taking active treatment. Table 4 shows reasons
for withdrawing from trial treatment for all men (ie regard-
less of treatment group), because blindness on this
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Figure 1
Summary of recruitment.aspect will be maintained until the main results are
reported. The withdrawal rate of 37.7% at 3 years was
higher than anticipated, but 80% of person-years at
3 years were spent on allocated treatment. The cumulative
proportions of persons who withdrew over 3 years are
shown in Fig. 2. One man had to withdraw because of
severe muscle pain associated with a raised creatine
kinase level. Nearly all those who withdrew because of
incompatible medication had begun treatment with a
statin. Withdrawals classified as ‘patient decision’ were for
a variety of mostly vague and unspecified reasons.
Fig. 3 shows the effects of treatment on lipids graphically,
and the percentage changes attributable to trial treatment
on these and other variables are summarized in Table 5.
Active treatment led to a sustained reduction in total cho-
lesterol of approximately 8%. There was an unexplained
downward ‘drift’ in LDL-cholesterol levels in the laboratory
Available online http://cvm.controlled-trials.com/content/2/4/195
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Table 1
Reasons for exclusion in 937 out of 2505 men screened
Reason n %
LEAD not confirmed 277 11.1
Patient unwilling 248 9.9
Lipid-modifying agent 87 3.5
Blood test results* 64 2.6
Renal or hepatic disease 45 1.8
Other significant disease  36 1.4
Unstable angina 17 0.7
Died before trial entry 15 0.6
Malignant disease 16 0.6
Other, unknown 132 5.3
Total 937 37.4
*At screening (eg raised creatinine).
Table 2
Characteristics of 1568 men entering the trial
Characteristic Values
Age (average years [range]) 68.6 (35–92)
Smoking (n [%])
Current 593 (37.8)
Ex 908 (57.9)
Never 67 (4.3)
Previous history (n [%])*
Myocardial infarction 332 (21.2)
Stroke 194 (12.4)
Stable angina 382 (24.4)
Blood pressure, mmHg (mean [SD])
Systolic 147.5 (21.7)
Diastolic 77.1 (11.5)
†Diabetes (n [%]) 268 (17.1)
‡Antiplatelet medication (n [%]) 1027 (65.5)
Fibrinogen, g/l (mean [SD]) 3.37 (0.60)
Total cholesterol, mmol/l (mean [SD]) 5.64 (0.93)
LDL-cholesterol, mmol/l (mean [SD]) 3.40 (0.86)
HDL-cholesterol, mmol/l (mean [SD]) 1.19 (0.36)
Triglycerides, mmol/l (mean [SD]) 2.40 (1.23)
*Some men with more than one condition. †Insulin (24%), oral therapy
(57%) and diet only (22%). ‡Aspirin (95%) and dipyridamole (5%).
Table 3
Numbers and percentage of men ever reporting specified
symptoms by treatment group, based on answers to 15,279
questionnaires
Active Placebo
Symptom n % n % P
Sickness 192 28.2 197 27.7 0.83
Indigestion 346 50.6 348 49.0 0.54
Full stomach 327 47.8 336 47.3 0.84
New muscular pains 430 62.9 449 63.2 0.91
Rash 182 26.6 208 29.3 0.27
Itching 321 46.9 344 48.4 0.59
Impotence 317 46.4 317 44.6 0.51
Table 4
Reasons for withdrawal from randomised trial treatment
among 1434 men followed for 3 years
Reason n*%
New disease 35 2.4
Incompatible medication 92 6.4
Adverse reaction 63 4.4
Other significant condition 43 3.0
Noncompliance 5 0.3
Moved away 13 0.9
Patient decision 193 13.5
Raised creatinine 24 1.7
Other 73 5.1
Total 541 37.7
*Data omitted for men in trial less than 3 years in March 2001.that analysed the samples, which is reflected in the
placebo group (and in all of the hospital’s routine clinical
samples analysed in the laboratory concerned). Neverthe-
less, the effect of active treatment in raising HDL-choles-
terol can be seen, although the difference declined from
10.6 to 6.2% over the 3 years. There may have been a
small increase in absolute LDL-cholesterol levels as a
result of the drift in HDL-cholesterol (because the calcu-
lated difference method has been used for LDL-choles-
terol), but the sustained difference between the two
groups represents a reduction of approximately 9% in
LDL-cholesterol at 3 years attributable to active treatment.
There was also a substantial reduction in triglyceride
levels, as expected. Fig. 4 shows that there was a sus-
tained reduction of approximately 14% in plasma fibrino-
gen attributable to active treatment.
Fig. 5a shows the expected rise in creatinine due to
bezafibrate administration, initially approximately 13% and
Current Controlled Trials in Cardiovascular Medicine    August 2001    Vol 2 No 4 Meade
Figure 2
Percentage of men withdrawing from randomised treatment during the
first 3 years.
Figure 3
Lipids up to 36 months since trial entry (adjusted for baseline differences between groups). (a) Total cholesterol; (b) LDL-cholesterol; (c) HDL-
cholesterol; and (d) triglycerides.falling to 10% at 3 years. Fig. 5b shows a fall of about
33% in alkaline phosphate. Table 6 shows the data for
alkaline phosphatase according to the proportions of men
with changes of the specified magnitudes, suggesting a
high level of compliance in those who remained on trial
treatment.
Fig. 6 shows effects on CRP and fibrinogen levels. There
were 96 men on active treatment and 92 on placebo at
each timepoint for both variables. There was no effect of
active treatment on CRP levels, but the effect on fibrino-
gen is confirmed. (Omission of those with CRP values of
over 20 mg/l at any stage – probably reflecting the further
short-term effect of an inflammatory response [e.g. respira-
tory tract infection] – also resulted in no difference
between the two groups.)
Discussion
Thus far, clinical endpoint results have been reported from
two randomised trials of bezafibrate.
The Bezafibrate Infarction Prevention trial [16,17] recruited
3090 male and female patients aged 45–74 years with an
established history of CHD (78% with myocardial infarc-
tion), who had fasting total cholesterol levels between 180
and 250 mg/dl and triglyceride levels of less than
300 mg/dl. Follow-up was for 6.2 years on average (range
4.7–7.6 years). Overall, the 9.4% reduction in the com-
bined primary endpoint of fatal or nonfatal myocardial
infarction or sudden death was not statistically significant.
In those whose triglyceride levels were 200 mg/dl or
greater, the 39.5% reduction was significant (P = 0.02),
whereas there was no difference among those with lower
levels. The net rise in HDL-cholesterol due to treatment
was 14.4% (i.e. greater than in LEADER). The reduction of
25.2% in triglyceride levels in that study was similar to the
reduction achieved in the LEADER trial, but the changes in
cholesterol of 4.7%, LDL-cholesterol of 5.2% and fibrino-
gen of 10% were rather less than in LEADER.
The Bezafibrate Coronary Atherosclerosis Intervention Trial
[18] was carried out in 92 survivors of myocardial infarction
who were younger than 45 years with a mean serum cho-
lesterol of at least 5.3 mmol/l and/or mean serum triglyc-
erides of at least 1.6 mmol/l. The main purpose of that trial
(which administered bezafibrate 200 mg three times a day)
was to determine whether treatment could retard or
prevent the progression of atherosclerotic lesions, as
assessed using coronary angiography at baseline and then
at 2, 3 and 5 years. This objective was achieved, and in
addition three of the 47 patients receiving active treatment
had coronary events as compared with 11 out of the 45
patients in the placebo group, a reduction of nearly 75%
(P = 0.019). Total cholesterol fell by 14%, LDL-cholesterol
by 3.5% and triglycerides by 26.3%. HDL-cholesterol rose
by 8.6%. Fibrinogen fell by 13.3%. Thus, the Bezafibrate
Available online http://cvm.controlled-trials.com/content/2/4/195
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Table 5
Percentage differences between active and placebo groups at different time points
Parameter 3/6 months (n = 1417) 1 year (n = 1156) 2 years (n = 917) 3 years (n = 723)
Total cholesterol 7.7 (6.7–8.7) 8.4 (7.0–9.7) 7.8 (6.3–9.3) 8.1 (6.3–9.9)
HDL-cholesterol 10.6 (8.9–12.2) 9.4 (7.2–11.6) 7.3 (5.1–9.6) 6.2 (3.3–9.1)
LDL-cholesterol 9.2 (7.5–10.9) 9.4 (7.2–11.6) 8.1 (5.6–10.6) 9.3 (6.1–12.5)
Triglycerides 23.0 (20.1–25.9) 23.3 (19.6–27.1) 25.4 (21.2–29.7) 23.4 (18.3–28.5)
Fibrinogen 12.4 (10.8–13.9) 14.4 (12.4–16.3) 14.2 (11.9–16.5) 13.2 (10.6–15.9)
Creatinine 13.1 (11.8–14.3) 13.2 (11.7–14.7) 11.6 (9.8–13.4) 9.4 (7.1–11.6)
Alkaline phosphatase 30.6 (29.0–32.1) 33.5 (29.5–37.6) 33.4 (30.6–36.3) 32.3 (29.3–35.2)
Percentage differences (95% confidence intervals) between active and placebo groups at 3/6 months (average), 1 year, 2 years and 3 years. For
statistical methods, see text. All group differences were significant, at P < 0.0001.
Figure 4
Plasma fibrinogen up to 36 months since trial entry (adjusted for
baseline differences between groups).Infarction Prevention trial and the Bezafibrate Coronary
Atherosclerosis Intervention Trial suggest that bezafibrate
may result in some reduction, of uncertain magnitude, in
major events of CHD.
The Diabetes Atherosclerosis Intervention Study, which
used micronized fenofibrate [19], recently reported lipid-
modifying effects very similar to those found in the present
study. In that study angiographic progression of coronary
artery disease was reduced by active treatment, and there
were 38 and 50 clinical endpoints among those on active
and placebo treatment, respectively, although the differ-
ence was not significant. Two trials using gemfibrozil
Current Controlled Trials in Cardiovascular Medicine    August 2001    Vol 2 No 4 Meade
Figure 5
Creatinine and alkaline phosphatase up to 36 months since trial entry
(adjusted for baseline differences between groups). (a) Total
creatinine (µmol/l); and (b) total alkaline phosphatase (u/l).
Figure 6
CRP and fibrinogen up to 6 months following trial entry, according to
allocated trial treatment. (a) CRP; and (b) fibrinogen.
Table 6
Changes in alkaline phosphatase at different time points
3–6 months 1 year 2 years 3 years
Number of patients and change in alkaline 
phosphatase Active Placebo Active Placebo Active Placebo Active Placebo
n 694 721 558 595 444 473 360 362
Decrease ≥20% 81.0 3.1 72.8 5.1 76.4 11.0 87.5 21.3
Decrease 0–20% 15.9 44.1 21.7 37.2 19.4 40.9 8.9 43.2
Increase 3.2 52.8 5.6 57.7 4.3 48.1 3.6 35.5
Percentage changes in alkaline phosphatase by treatment group between baseline and 3–6 months, and 1, 2 and 3 years, as a measure of
compliance.[20,21], which has different properties from those of
bezafibrate and fenofibrate, showed that it significantly
reduces clinical endpoints.
Like the other fibrate trials, the LEADER trial was con-
ducted primarily to test whether a fibrate reduces CHD
and stroke by whatever mechanism(s). Assuming that
bezafibrate does reduce clinical endpoints in the LEADER
trial, a further question will be how far the benefit can be
attributed to its fibrinogen-lowering or lipid-modifying
effects, or both. Using Cox proportional hazards models,
the independent contributions to the risk of CHD and
stroke of changes in fibrinogen and, say, total cholesterol
between recruitment and the various follow-up intervals
will be estimated for all men and for those on active or
placebo treatment. This approach is very similar to that
used in the Veterans Affairs High-Density Lipoprotein
Intervention Trial [22]. Analyses from that study showed
that the effect of gemfibrozil treatment on HDL-cholesterol
predicted a significant reduction in CHD, independent of
changes in LDL-cholesterol and triglyceride levels. The
possibility in the Bezafibrate Infarction Prevention trial [17]
that bezafibrate was beneficial in those with high triglyc-
eride levels provides an a priori hypothesis for analysing
LEADER to determine whether there is an interaction
between triglyceride values at entry and response to treat-
ment, particularly because the main effect of bezafibrate is
on triglycerides.
Trial participants in LEADER have come from general
practices and hospital vascular clinics throughout the UK
and a high proportion (some 86%) of those eligible have
entered. Consequently, the main results are likely to have
general applicability and the entry characteristics of the
participants provide a useful profile of LEAD in the com-
munity. Nearly all men are or had been smokers, only 4%
claiming never to have smoked. As expected, many had
already developed clinically manifest arterial disease.
Perhaps somewhat unexpectedly, entry values of fibrino-
gen and lipids were not grossly abnormal, entry fibrinogen
and (non-fasting) triglyceride values being only moderately
raised. The full reduction in fibrinogen levels in LEADER
appeared to occur only after approximately 6 months on
treatment (Fig. 4).
Bezafibrate did not lead to any excess of the mainly gas-
trointestinal symptoms that are often associated with it,
and other symptoms such as rashes or impotence did not
differ between the groups. The proportion of patients who
withdrew from randomised treatment was higher than was
assumed in our estimation of the required sample size.
However, extending the duration of participation for men
recruited early on has to some extent offset the effect of
this difference, and many withdrawals occurred after
several years of participation in the trial. Thus, even at 3
years, some 80% of the person-years accrued in the trial
were spent on randomly assigned treatment. The results
on alkaline phosphatase indicate a high level of compli-
ance in those continuing with treatment.
It has been suggested that fibrates may increase mortality
from other conditions, including cancer [23], although this
remains controversial. Much the greatest risk to the gener-
ally elderly men in the trial is from arterial disease,
however, so that any possible increase in cancer inci-
dence would need to be balanced against any reduction in
CHD and stroke due to bezafibrate.
The extent to which the raised fibrinogen levels associated
with arterial disease are due to the inflammatory character-
istics of atheroma or inflammation and/or infection is
debated. The contrast between the fibrinogen-lowering
effect of bezafibrate and the absence of any effect on CRP
is clear. CRP is a particularly sensitive index of inflamma-
tory processes. Thus, it appears that the effect of bezafi-
brate on fibrinogen is independent at any rate of this index
of inflammation, suggesting that any benefit due to bezafi-
brate on fibrinogen levels may not be mediated simply
through a reduction in inflammatory stimuli. CRP levels in
patients with LEAD are clearly raised, with the geometric
mean being more than 3.5 mg/l in contrast to the median
value of 0.8 mg/l in volunteer blood donors [24] and the
geometric mean of 2.03 mg/l among 464 unselected men
aged 64–75 years in the general population [25].
Further data on the effect of fibrates are needed for com-
parison with the larger body of evidence on statins and in
view of recent reports that indicate that bezafibrate may
raise homocysteine levels [26], and thus the risk of vascu-
lar events if homocysteine is eventually shown conclu-
sively to contribute to these.
In conclusion, a high proportion (86%) of eligible patients
with LEAD were recruited. Despite withdrawals from ran-
domised treatment, 80% of person-years were spent on
allocated treatment at 3 years. There were no differences
between those on active and placebo treatment in antici-
pated side effects. As expected, active treatment led to
lipid modifications that would be expected to be benefi-
cial, particularly the lowering of triglyceride levels, and
there is a strong a priori case for analysing the main clini-
cal endpoint results to determine whether there may be an
interaction between initial triglycerides level and any
benefit conferred by bezafibrate. There has been a sus-
tained reduction in plasma fibrinogen that would also be
expected to be beneficial. There is, however, no clear
effect of treatment on CRP. Thus, any benefit due to
bezafibrate on fibrinogen may not be mediated simply
through a reduction in inflammatory stimuli.
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